BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford
What can Homer teach us about biotech? Has Big Science gotten too big? And what's the future of treating Alzheimer's disease? All that and more on the new episode of…
What can Homer teach us about biotech? Has Big Science gotten too big? And what’s the future of treating Alzheimer’s disease?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literature remains relevant. We also discuss the latest news in the life sciences, including the abrupt resignation of the celebrity scientist who led Stanford University and the implications of tornado damage at a Pfizer plant.
What's Your Reaction?
